DE69621012D1 - VERWENDUNG VON NSAIDs ZUR BEHANDLUNG VON PLATTENEPITHELKARZINOM DER MUNDHÖHLE UND KEHLKOPF - Google Patents

VERWENDUNG VON NSAIDs ZUR BEHANDLUNG VON PLATTENEPITHELKARZINOM DER MUNDHÖHLE UND KEHLKOPF

Info

Publication number
DE69621012D1
DE69621012D1 DE69621012T DE69621012T DE69621012D1 DE 69621012 D1 DE69621012 D1 DE 69621012D1 DE 69621012 T DE69621012 T DE 69621012T DE 69621012 T DE69621012 T DE 69621012T DE 69621012 D1 DE69621012 D1 DE 69621012D1
Authority
DE
Germany
Prior art keywords
oral cavity
treatment
cell carcinoma
squamous cell
nsaids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69621012T
Other languages
English (en)
Other versions
DE69621012T2 (de
Inventor
Francis Cavanaugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of DE69621012D1 publication Critical patent/DE69621012D1/de
Application granted granted Critical
Publication of DE69621012T2 publication Critical patent/DE69621012T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69621012T 1995-03-13 1996-02-21 VERWENDUNG VON NSAIDs ZUR BEHANDLUNG VON PLATTENEPITHELKARZINOM DER MUNDHÖHLE UND KEHLKOPF Expired - Fee Related DE69621012T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/402,587 US5626838A (en) 1995-03-13 1995-03-13 Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
PCT/US1996/002386 WO1996028144A1 (en) 1995-03-13 1996-02-21 Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx

Publications (2)

Publication Number Publication Date
DE69621012D1 true DE69621012D1 (de) 2002-06-06
DE69621012T2 DE69621012T2 (de) 2002-12-05

Family

ID=23592530

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69621012T Expired - Fee Related DE69621012T2 (de) 1995-03-13 1996-02-21 VERWENDUNG VON NSAIDs ZUR BEHANDLUNG VON PLATTENEPITHELKARZINOM DER MUNDHÖHLE UND KEHLKOPF

Country Status (10)

Country Link
US (2) US5626838A (de)
EP (1) EP0814784B1 (de)
JP (1) JPH11502196A (de)
AT (1) ATE216877T1 (de)
CA (1) CA2214097C (de)
DE (1) DE69621012T2 (de)
DK (1) DK0814784T3 (de)
ES (1) ES2172654T3 (de)
PT (1) PT814784E (de)
WO (1) WO1996028144A1 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2742054B1 (fr) * 1995-12-06 1998-01-09 Synthelabo Compositions pharmaceutiques contenant un agent anti-inflammatoire et des ceramides vegetales
US5939047A (en) * 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
US20030206874A1 (en) * 1996-11-21 2003-11-06 The Proctor & Gamble Company Promoting whole body health
US5916575A (en) * 1997-01-27 1999-06-29 The Procter & Gamble Company Cleaning products
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
US6399093B1 (en) 1999-05-19 2002-06-04 Advanced Medical Instruments Method and composition to treat musculoskeletal disorders
IL150925A0 (en) * 2000-02-01 2003-02-12 Little Inc A Chemical and/or biological decontamination system
JP2003530437A (ja) * 2000-04-13 2003-10-14 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Ａβ４２低下物質
WO2002002096A2 (en) * 2000-06-30 2002-01-10 The Procter & Gamble Company Oral compositions comprising host-response modulating agent
EP1294383B1 (de) * 2000-06-30 2008-07-16 The Procter & Gamble Company Orale zubereitungen, die antimikrobielle wirkstoffe enthalten zur prävention von systemischen erkrankungen
US8283135B2 (en) * 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
CA2464228C (en) * 2000-10-27 2017-01-17 Immuno-Rx, Inc. Vaccine immunotherapy for immune suppressed patients
US6576226B1 (en) 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6726898B2 (en) 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
ITMI20020986A1 (it) * 2002-05-10 2003-11-10 Acraf Composizione a base di diclofenac per il trattamento topico di affezioni del cavo orofaringeo
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
BRPI0302736B8 (pt) * 2003-06-02 2021-05-25 Ems S/A composição farmacêutica a base de cetorolaco ou de um de seus sais farmaceuticamente aceitáveis para uso sublingual
US20050042284A1 (en) * 2003-07-11 2005-02-24 Myriad Genetics, Incorporated Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
WO2005016354A1 (en) * 2003-08-19 2005-02-24 Werner Kreutz Diflunisal for the treatment of cancer
US20050143274A1 (en) 2003-12-17 2005-06-30 Ghosh Chanchal K. Compositions and methods of delivering bleaching agents to teeth
ITMI20032523A1 (it) * 2003-12-19 2005-06-20 Acraf Forma di dosaggio per uso orale comprendente un farmaco
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
JP2005343802A (ja) * 2004-05-31 2005-12-15 Norifumi Sakayama 非ステロイド性消炎鎮痛剤の外用剤を用いた癌細胞の増殖を抑制する方法
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
ES2747926T3 (es) * 2004-09-27 2020-03-12 Special Water Patents B V Métodos y composiciones para el tratamiento de agua
EA200800360A1 (ru) * 2005-07-22 2008-06-30 Мириад Дженетикс, Инк. Формуляции с высоким содержанием лекарства и дозированные формы
US20090104242A1 (en) * 2005-07-28 2009-04-23 Indiana University Research & Technology Corporati Niobium oxide compositions, nanostructures, bioactive forms and uses thereof
EP1948236B1 (de) 2005-09-27 2021-03-03 Special Water Patents B.V. Methoden und zusammensetzungen zur behandlung der haut
US20070178220A1 (en) * 2006-01-31 2007-08-02 Karlinsey Robert L Materials and methods for manufacturing amorphous tricalcium phosphate and metal oxide alloys of amorphous tricalcium phosphate and methods of using the same
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
BRPI0721709B1 (pt) * 2007-06-04 2024-03-12 Techfields Inc. PRÓ-FÁRMACOS DE NSAIAs, PROCESSO PARA PREPARAÇÃO DOS MESMOS, SEU USO, SISTEMAS TERAPÊUTICOS DE APLICAÇÃO TRANSDÉRMICA E COMPOSIÇÃO QUE OS COMPREENDE
WO2009087658A2 (en) * 2007-11-07 2009-07-16 Sun Pharma Advanced Research Company Limited Composition suitable for parenteral administration
US8956641B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US8956636B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
US8846068B2 (en) 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US9072727B2 (en) * 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US9132085B2 (en) * 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US8722079B2 (en) * 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US9700525B2 (en) 2008-08-20 2017-07-11 Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College Continuous local slow-release of therapeutics for head and neck problems and upper aerodigestive disorders
US20100098746A1 (en) * 2008-10-20 2010-04-22 Warsaw Orthopedic, Inc. Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
US8211408B2 (en) 2008-11-25 2012-07-03 The Proctor & Gamble Company Low pH oral care compositions with fused silica
TWI383802B (zh) 2008-12-04 2013-02-01 Chongxi Yu 高滲透性組合物及其應用
US8980317B2 (en) * 2008-12-23 2015-03-17 Warsaw Orthopedic, Inc. Methods and compositions for treating infections comprising a local anesthetic
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8231891B2 (en) 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
US8623388B2 (en) 2009-10-29 2014-01-07 The Procter & Gamble Company Denture care composition
US9486500B2 (en) 2010-01-28 2016-11-08 Warsaw Orthopedic, Inc. Osteoimplant and methods for making
US9125902B2 (en) 2010-01-28 2015-09-08 Warsaw Orthopedic, Inc. Methods for treating an intervertebral disc using local analgesics
US9050274B2 (en) 2010-01-28 2015-06-09 Warsaw Orthopedic, Inc. Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents
NZ601989A (en) * 2010-02-12 2014-11-28 Theocorp Holdings Co Llc Methods and compositions to improve mechanical resistance of teeth
US9125899B1 (en) 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
US8740982B2 (en) 2010-10-26 2014-06-03 Kyphon Sarl Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis
US8404268B2 (en) 2010-10-26 2013-03-26 Kyphon Sarl Locally targeted anti-fibrotic agents and methods of use
US9414930B2 (en) 2010-10-26 2016-08-16 Kyphon SÀRL Activatable devices containing a chemonucleolysis agent
WO2012075451A2 (en) 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Clonidine and gaba compounds in a biodegradable polymer carrier
WO2012075447A2 (en) 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Compositions and methods for delivering clonidine and bupivacaine to a target tissue site
US9060978B2 (en) 2011-01-24 2015-06-23 Warsaw Orthopedic, Inc. Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist
US9511077B2 (en) 2011-04-25 2016-12-06 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for wound healing
US9592243B2 (en) 2011-04-25 2017-03-14 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for treatment of an injury
US9511018B2 (en) 2012-04-05 2016-12-06 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable matrix
EP4356912A2 (de) 2012-05-16 2024-04-24 Techfields Pharma Co., Ltd. Prodrug-zusammensetzungen mit hoher penetration und pharmazeutische zusammensetzung daraus zur behandlung von lungenerkrankungen
EP2700396A3 (de) 2012-06-20 2015-04-29 Sylphar Nv Streifen zur Abgabe einer Mundpflegezusammensetzung
US10285915B2 (en) 2012-10-17 2019-05-14 The Procter & Gamble Company Strip for the delivery of an oral care active and methods for applying oral care actives
CN104768520B (zh) 2012-11-05 2017-06-13 宝洁公司 热处理的沉淀二氧化硅
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
US20150210964A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Consumer Product Compositions
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US10080877B2 (en) 2014-07-25 2018-09-25 Warsaw Orthopedic, Inc. Drug delivery device and methods having a drug cartridge
US9326925B1 (en) 2015-02-26 2016-05-03 Johnson & Johnson Consumer Inc. Compositions comprising combinations of organic acids
EP3261610B1 (de) 2015-02-26 2019-12-18 Johnson & Johnson Consumer Inc. Zusammensetzungen mit kombinationen aus organischen säuren
US9326924B1 (en) 2015-02-26 2016-05-03 Johnson & Johnson Consumer Inc. Compositions comprising combinations of organic acids
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
USD802755S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
WO2018197932A1 (en) * 2017-04-27 2018-11-01 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of ketorolac
AU2018316205A1 (en) 2017-08-09 2020-02-06 The Procter & Gamble Company Aptamers for oral care applications
MX2017015623A (es) * 2017-12-04 2018-11-09 Federico Amezcua Amezcua Novedoso compuesto quimico que contiene el enantiomero activo s-(-) ketorolaco trometamina para el tratamiento del dolor.
US20190175486A1 (en) 2017-12-07 2019-06-13 Johnson & Johnson Consumer Inc. Oral Care Compositions
US20190175487A1 (en) 2017-12-07 2019-06-13 Johnson & Johnson Consumer Inc. Oral Care Compositions
US11172873B2 (en) 2018-05-17 2021-11-16 The Procter & Gamble Company Systems and methods for hair analysis
JP7140848B2 (ja) 2018-05-17 2022-09-21 ザ プロクター アンド ギャンブル カンパニー 毛髪被覆率分析のためのシステム及び方法
CN112771164A (zh) 2018-06-29 2021-05-07 宝洁公司 用于个人护理应用的适配体
EP3956451A1 (de) 2019-04-16 2022-02-23 The Procter & Gamble Company Aptamere für geruchsunterdrückungsanwendungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1207994B (it) * 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
ATE303157T1 (de) * 1990-01-17 2005-09-15 David S Terman Verwendung von staphylococcus-enterotoxinen oder verwandte verbindungen für krebs-therapie
DK0519983T3 (da) * 1990-03-16 1996-10-14 Procter & Gamble Anvendelse af ketorolac til behandling af periodontal sygdom
US5464609A (en) * 1990-03-16 1995-11-07 The Procter & Gamble Company Use of ketorolac for treatment of oral diseases and conditions
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid

Also Published As

Publication number Publication date
PT814784E (pt) 2002-09-30
CA2214097C (en) 2002-07-16
ES2172654T3 (es) 2002-10-01
EP0814784B1 (de) 2002-05-02
ATE216877T1 (de) 2002-05-15
USRE36419E (en) 1999-11-30
DE69621012T2 (de) 2002-12-05
US5626838A (en) 1997-05-06
DK0814784T3 (da) 2002-06-17
WO1996028144A1 (en) 1996-09-19
EP0814784A1 (de) 1998-01-07
JPH11502196A (ja) 1999-02-23
CA2214097A1 (en) 1996-09-19

Similar Documents

Publication Publication Date Title
DE69621012T2 (de) VERWENDUNG VON NSAIDs ZUR BEHANDLUNG VON PLATTENEPITHELKARZINOM DER MUNDHÖHLE UND KEHLKOPF
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
MY119403A (en) Novel compounds with analgesic effect.
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
ATE142877T1 (de) Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
DE69710065D1 (de) Androsten-derivate
HUP0001014A2 (hu) Gasztrointesztinális lipáz inhibitorok felhasználása
DE69713300D1 (de) Benzopyran derivate mit leukotrien-antagonistischer wirkung
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
AU3600199A (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
ATE137967T1 (de) Verwendung von ketorolac zur behandlung von periodontitis
CA2197139A1 (en) A drug for the treatment of cancer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CORNELL UNIVERSITY, ITHACA, N.Y., US

8339 Ceased/non-payment of the annual fee